SCHEMBL5759503

SCHEMBL5759503

Clc1cccc2c1NCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.49
MAPT P10636 2/20 0.49
PNMT P11086 2/20 0.43
AHR P35869 1/20 0.43
GAA P10253 2/20 0.41
HTR5A P47898 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
MPI P34949 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HDAC4 P56524 1/20 0.40
HTR2C P28335 2/20 0.38
TAAR1 Q96RJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878574 0.88 MAPT (0.56) SRCMAPTPNMTAHRGAA
SCHEMBL3717293 0.76 PNMT (0.53) SRCMAPTPNMTGAAKDM4E
SCHEMBL13977383 0.76 SRC (0.49) SRCMAPTKDM4EHTR2CTSHR
SCHEMBL327043 0.76 SRC (0.53) SRCMAPTPNMTGAAKDM4E
SCHEMBL6359546 0.76 SRC (0.53) SRCMAPTKDM4EHDAC4HTR2C
SCHEMBL17969105 0.76 SRC (0.49) SRCMAPTKDM4EHTR2CTSHR
SCHEMBL342322 0.76 SRC (0.49) SRCMAPTHTR5AKDM4EALDH1A1
SCHEMBL6796232 0.76 SRC (0.49) SRCPNMTKDM4EMEN1KMT2A
SCHEMBL1082367 0.76 SRC (0.49) SRCMAPTGAAKDM4EMEN1
SCHEMBL29661329 0.76 SRC (0.49) SRCMAPTGAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119702019-A Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof 湘潭大学 2025-03-28 CN claimed
US-7101869-B2 2,4-diaminopyrimidine compounds useful as immunosuppressants PFIZER INC. (US) 2006-09-05 US claimed
EP-1242403-B1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS PFIZER PROD INC (US) 2006-01-04 EP claimed
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants BLUMENKOPF TODD A (US) 2003-10-09 US claimed
EP-1242403-A1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS Pfizer Products Inc. (US) 2002-09-25 EP claimed
WO-2001040215-A1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO claimed
CN-119702019-A Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof 湘潭大学 2025-03-28 CN disclosed
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO PHARMA (FR) 2023-05-18 US disclosed
EP-4126847-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER ENYO Pharma (FR) 2023-02-08 EP disclosed
CN-113717098-B Method for synthesizing tetrahydroquinoline compound by selectively catalyzing and hydrogenating quinoline compound with non-hydrogen 延安大学 2023-02-03 CN disclosed
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2022-07-07 US disclosed
WO-2022087624-A1 COMPOUNDS AS RAS INHIBITORS AND USES THEREOF BIOARDIS LLC (US) 2022-04-28 WO disclosed
WO-2022087624-A1 COMPOUNDS AS RAS INHIBITORS AND USES THEREOF BIOARDIS LLC (US) 2022-04-28 WO disclosed
EP-1242403-A1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS Pfizer Products Inc. (US) 2002-09-25 EP disclosed
WO-2001040215-A1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO disclosed
EP-0216028-A2 Use of anthranilic-acid derivatives as anthelmintic medicaments HOECHST AKTIENGESELLSCHAFT (DE) 1987-04-01 EP disclosed
US-4623377-A PREEMERGENCE NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-11-18 US disclosed
EP-0158954-A2 Tetrahydroquinolin-1-yl carbonyl imidazole derivatives, their intermediates; process for their preparation and herbicides or fungicides for agriculture or horticulture NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1985-10-23 EP disclosed
EP-0008439-B1 PYRANO-HETEROCYCLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM HOECHST AKTIENGESELLSCHAFT (DE) 1982-04-14 EP disclosed
EP-0008439-A1 Pyrano-heterocycles, process for their preparation and pharmaceutical compositions containing them HOECHST AKTIENGESELLSCHAFT (DE) 1980-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150978-A1 QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER NQO2, NQO1, NDUFV2 SRC 2074/4885MAPT 4272/4885PNMT 2451/4885
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants CCR1, AOC1, NOD1 SRC 3262/4885MAPT 4588/4885PNMT 2920/4885
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI, TFPI2, SERPINC1 SRC 4245/4885MAPT 4590/4885PNMT 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.